Reviewer's report

Title: Pfizer's antifungal trials of voriconazole are misleading because of flaws in design, analysis and interpretation

Version: 1 Date: 21 November 2005

Reviewer: Rodrigo Martino

Reviewer's report:

The Brief Report by Jorgensen et al. is a clear reminder of how complex analysing studies with antifungals can be. The specific problems with voriconazole have been extensively recognised in the literature, and the authors cite their own previous manuscripts on this matter several times. Thus, there is nothing really very novel in the criticisms pointed out by this report.

However, as a reminder to clinicians who are not experts in statistics and fungal infections this report may be of help in "opening their eyes". Nevertheless, I strongly suggest that the authors don't focus all their complaints against voriconazole and recognise that most other trials suffer similar, if not even greater defects.

Declaration of competing interests:

In the past five years received reimbursements for travel expenses to meetings and fees for giving talks in antifungal symposia by several drug companies who market antifungals: Merck, Medeus Pharma and Pfizer.